AVXL - Anavex Life Sciences Forward P/S Multiple
Anavex Life Sciences is developing innovative methods to combat Parkinson's and Alzheimer's diseases, leveraging the potential of blarcamesine. The expected P/S ratio reflects the market valuation dynamics relative to revenue forecasts, where expresses the current level of the metric. However, the lack of profitability and dependence on FDA verdicts create significant risks, while the asset's capitalization completely ignores economic cycles.
Comprehensive metric breakdowns and analytics for anavex.com (AVXL)
- market price and analyst price targets:
- market capitalization statistics:
- issuer book value statistics:
- company liabilities and liquidity data:
Total Debt to Equity Ratio Anavex Life Sciences|AVXL - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Anavex|AVXL - Company Total Debt Obligations|Debts to Book Capitalization Anavex|AVXL - Company Long-Term Liabilities|Company Short-Term Debts Anavex Life Sciences|Quick Ratio anavex.com
- financial results and valuation multiples details:
AVXL - Company Net Income|Expected Profit Anavex Life Sciences|AVXL - Price to Earnings Multiple|Forward P/E Multiple anavex.com|AVXL - Price/Earnings to Growth Multiple|EV/EBITDA Multiple Anavex Life Sciences Corp|AVXL - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Anavex Life Sciences|AVXL - Net earnings per share for the last four quarters|Quarterly EPS earnings growth anavex.com|AVXL - Earnings growth in current year|Expected earnings per share growth for next year Anavex Life Sciences
- sales volume and revenue information:
Comprehensive company analysis:Anavex Life Sciences Corp AVXL
Anavex Life Sciences focuses on developing neurological drugs, where research efficacy depends on the precision of global supply chain logistics. This indicator compares current market capitalization with expected future revenues, neutralizing the emotional volatility of quarterly reports. This helps the investor determine the fair value of the business by assessing the risk of overpaying for promising developments. Analysis based on the forward price-to-sales ratio allows for the identification of the asset's margin of safety across various market scenarios.
Competitors of Anavex Life Sciences (AVXL)
Forward P/S Multiple BIIB (Biogen Idec)|Market Cap to Expected Sales Ratio Neurocrine Corp (NBIX)|RGC: Forward Price-to-Revenue Multiple|Forward Price to Sales AXSM (Axsome Therapeutics)|ACAD: Forward P/S Multiple|Xenon Pharmaceuticals Inc. - Forward Price to Sales|Price-to-Projected Revenue Ratio Viking Pharma|SUPN: Forward Price to Sales|Forward P/S Multiple CPRX|Forward P/S Multiple denalitherapeutics.com (DNLI)|Forward P/S Multiple HRMY (Harmony Biosciences Inc)|Market Cap to Expected Sales Ratio Biohaven (BHVN)|Amylyx Corp - Forward P/S Multiple|TRVI - Forward P/S Multiple|Praxis Precision Medicines Inc (PRAX) - Price-to-Projected Revenue Ratio|CBLL (ceribell.com) - Price-to-Projected Revenue Ratio|PRTA (Prothena Corporation) - Forward P/S Multiple|Forward Price-to-Revenue Multiple alector.com (ALEC)|Price-to-Projected Revenue Ratio Annexon, Inc. (ANNX)|OMER - Market Cap to Future Revenue Ratio|Forward P/S Multiple NGNE (Neurogene Inc)|AC Immune (ACIU) - Market Cap to Future Revenue Ratio|Voyager Therapeutics Inc - Forward P/S Multiple|Neumora (NMRA) - Forward Price-to-Revenue Multiple|SCLX: Forward P/S Multiple|TVGN - Market Cap to Expected Sales Ratio|ACOG (Alpha Cognition Inc) - Forward P/S Multiple|Forward Price-to-Revenue Multiple cogrx.com (CGTX)|Price-to-Projected Revenue Ratio Inhibikase Therapeutics Inc (IKT)|Market Cap to Expected Sales Ratio Cassava Sciences|Forward P/S Multiple ASRT (Assertio Holdings)|COYA - Forward Price-to-Revenue Multiple|vistagen.com - Forward P/S Multiple|OVID: Price-to-Projected Revenue Ratio|Acumen Pharmaceuticals, Inc (ABOS) - Price-to-Projected Revenue Ratio|CervoMed Inc - Forward Price to Sales|Price-to-Projected Revenue Ratio Alterity Therapeutics Limited|clene.com (CLNN) - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple PEPG (PepGen Inc)|Forward P/S Multiple jupiterneurosciences.com (JUNS)|Price-to-Projected Revenue Ratio Relmada Therapeutics, Inc. RLMD|ANVS: Market Cap to Projected Revenue|Grace Tx - Forward P/S Multiple|AIFF (Firefly Neuroscience Inc) - Market Cap to Projected Revenue|KLTO: Forward P/S Multiple|NeuroSense Therapeutics, Ltd. (NRSN) - Forward P/S Multiple|Price-to-Projected Revenue Ratio Reviva Pharmaceuticals, Inc.|Forward Price-to-Revenue Multiple metaviatx.com (MTVA)|Forward P/S Multiple NRXS|HSDT - Market Cap to Future Revenue Ratio|Passage Bio, Inc. - Forward Price-to-Revenue Multiple|bionomics.com.au (NEUP) - Market Cap to Future Revenue Ratio|Minerva - Forward P/S Multiple|Forward Price to Sales ATHA (Athira Pharma Inc)|ADXN: Forward P/S Multiple|Market Cap to Projected Revenue ALZN|CYCN (Cyclerion Therapeutics Inc.) - Forward P/S Multiple|PTIX (Protagenic Therapeutics) - Price to Expected Revenue Ratio|Forward P/S Multiple KTTA|Market Cap to Expected Sales Ratio Cortigent|Forward P/S Multiple ATXI (avenuetx.com)|BrainStorm Cell Therapeutics Inc. - Price-to-Projected Revenue Ratio|Cara Therapeutics Inc. - Forward P/S Multiple|Chromocell Therapeutics (CHRO) - Forward Price-to-Revenue Multiple|ELYM: Forward P/S Multiple|Forward Price-to-Revenue Multiple Intra-Cellular Therapies Inc.|LBPH (Longboard Pharmaceuticals Inc) - Forward P/S Multiple|Marinus - Future Price to Revenue|Forward P/S Multiple NKGN|NRBO (NeuroBo Pharmaceuticals) - Forward Price to Sales|Forward P/S Multiple SAGE (Sage Therapeutics Inc)|Market Cap to Expected Sales Ratio Synaptogenix Inc. (SNPX)|TRVN - Price-to-Projected Revenue Ratio|vigilneuro.com (VIGL) - Forward Price-to-Revenue Multiple|WENA: Forward P/S Multiple|Cerevel Therapeutics, Inc. (CERE) - Forward P/S Multiple
